Zoetis Q3 2026 net income drops 18% to $591 million

Bitget2026/11/05 12:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zoetis’ third-quarter 2026 net income fell 18% to $591 million, while revenue declined to $2.39 billion.
U.S. companion animal revenue dropped 8% to $980 million, reflecting macro-driven price sensitivity, dermatology competitive pressure and generic competition.
Convenia RTU for Dogs received FDA approval in October, with availability to veterinarians expected in the first quarter of 2027.
Full-year 2026 guidance narrowed revenue to $9.22 billion–$9.32 billion, while reported diluted EPS guidance fell to $5.50–$5.60.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104076504) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zoetis Q3 2026 net income drops 18% to $591 million

You may also like

Crypto prices